Status:
SUSPENDED
Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis
Lead Sponsor:
University of Pecs
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Meta-and ortho-Tyrosine are known markers of oxidative stress, while the physiological isomer, para-Tyrosine is suggested the antagonize the effects of meta- and ortho-Tyrosine. The changes in the ser...
Detailed Description
Data suggest, that among the amino acids, the meta- and ortho- isomers of tyrosine are potential markers of oxydative stress. The changes in their serum levels (and urinary excretion) in sepsis were f...
Eligibility Criteria
Inclusion
- Subjects must meet the following inclusion criteria to be eligible for the study:
- Are able to provide written informed consent (either the patient or the person entitled by legislation to consent on behalf of the patient)
- Male and female patients ≥ 18 years
- Have a current primary diagnosis of sepsis based on the the third international consensus definitions for sepsis and septic shock (Sepsis-3)Willing and able to comply with all aspects of the protocol
- Females of childbearing potential must have negtive serum pregnancy test az screening. (All females will be considered to be of childbearing potential unless they are postmenopausal i.e. amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause or have been sterilized surgically i.e. bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
Exclusion
- Subjects must not have any of the following criteria to be eligible for the study:
- Females who are pregnant (positive β-hCG test at screening) or breastfeeding
- chronic use of steroids or immunosuppressive drugs within the past 3 months
- other therapy influencing the immune system within the past 3 months (radiotherapy, chemotherapy etc.)
- malignant hematologic disease
- jejunal tube feeding
- any other significant illness in the medical history ongoing in the preceeding 1 month, which may have an influence on the survival and clinical outcome of the patients (e.g severe chronic heart failure NYHA III-IV., AMI, stroke, major surgery, COPD, renal failure, hepatic failure, hepatic cirrhosis etc.)
- Life expectancy less, than 1 months according to the judgement of the Investigator (even without significant illness, due to age or general status of the patient)
- Hypersensitivity to any of the excipients of the study product
- Known to be human immunodeficiency virus (HIV) positive
- Active viral hepatitis (B or C) as demonstrated by positive serology
- History of drug or alcohol dependency or abuse within approximately the last 2 years
Key Trial Info
Start Date :
January 1 2027
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2027
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT03278730
Start Date
January 1 2027
End Date
February 28 2027
Last Update
March 30 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Department of Medicine and Nephrological Center
Pécs, Baranya, Hungary, 7624
2
Department of Anaesthesiology and Intensive Care
Pécs, Baranya, Hungary, 7624